KFDA approves additional indication of Janumet
Published: 2011-09-19 06:56:00
Updated: 2011-09-19 06:56:00
The Korea Food and Drug Administration has recently approved the additional indication of Janumet (sitagliptin+metformin), the first and only tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor, for the treatment of type 2 diabetes.
The approved indication is the co-administration of J...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
